Which is the top player for the cardiovascular safety? ibrutinib vs. obinutuzumab in CLL

• Main Authors: Annamaria Mascolo (Author), Raffaella Di Napoli (Author), Nunzia Balzano (Author), Elena D'Alessio (Author), Imma Izzo (Author), Francesco Rossi (Author), Giuseppe Paolisso (Author), Annalisa Capuano (Author), Liberata Sportiello (Author)
• Format: Book
• Published: Frontiers Media S.A., 2023-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Introduction: Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, is authorized for the treatment of chronic lymphocytic leukemia (CLL). This study aims to explore the cardiac safety profile of ibrutinib in comparison with obinutuzumab.Methods: A retrospective pharmacovigilance study was con...